Jennison Associates
LBRX

Jennison Associates’s LB Pharmaceuticals LBRX Stock Holding History

Jennison Associates’s Portfolio LBRX Stock Details LBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$13.3M Sell
538,216
-283,636
-35% -$6.54M 0.01% 359
2025
Q4 		$18.3M Buy
821,852
+82,812
+11% +$1.45M 0.01% 349
2025
Q3 		$11.7M Buy
+739,040
New +$11.7M 0.01% 363

Other funds holding LBRX

DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
SSC
Spruce Street Capital New York $416M AUM
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $437M AUM
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Jennison Associates's LBRX Position: Q1 2026 in Review

Jennison Associates reduced its LB Pharmaceuticals (LBRX) stake by 35% in Q1 2026, selling an estimated $6.54M and leaving 538,216 shares worth $13.3M. The position accounts for 0.01% of the portfolio, ranked #359.

Jennison Associates first reported a position in LBRX in Q3 2025 and has held it in 3 quarters since. The position peaked at $18.3M in Q4 2025. 77 funds tracked by Wall St. Rank hold LBRX as of Q1 2026.

  • Jennison Associates held 538,216 shares of LB Pharmaceuticals worth $13.3M as of Q1 2026.
  • Jennison Associates sold 283,636 LB Pharmaceuticals shares in Q1 2026, an estimated $6.54M.
  • LB Pharmaceuticals made up 0.01% of Jennison Associates's portfolio in Q1 2026, its #359 holding.
  • Jennison Associates first reported a position in LB Pharmaceuticals in Q3 2025 and has held it in 3 quarters since.
  • Jennison Associates's LB Pharmaceuticals position peaked at $18.3M in Q4 2025.
  • 77 funds tracked by Wall St. Rank held LB Pharmaceuticals as of Q1 2026.

Based on Jennison Associates's 13F filing for Q1 2026, filed 6 May 2026.